Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 3 Study of NTLA-2001 in ATTRv-PN

This study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.

Participants needed: 60
Trial details
Phase: Phase 3Age: 18-85Biological sex: AllType: InterventionalSponsor: Intellia TherapeuticsUpdated: Apr 16, 2026Locations: 14
Eligibility criteria

Diagnosis of ATTRv-PN [+1]

Other causes of amyloidosis (amyloidosis caused by non-TTR protein) [+9]

Status: Recruiting

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Participants needed: 1,200
Trial details
Phase: Phase 3Age: 18-90Biological sex: AllType: InterventionalSponsor: Intellia TherapeuticsUpdated: Mar 27, 2026Locations: 132
Eligibility criteria

Documented diagnosis of ATTR amyloidosis with cardiomyopathy [+3]

New York Heart Association (NYHA) Class IV HF [+9]

Status: Recruiting

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Participants needed: 72
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Intellia TherapeuticsUpdated: Aug 26, 2025Locations: 4
Eligibility criteria

A subject has completed or discontinued from an Intellia-sponsored clinical stud... [+1]